Skip to main content

Table 5 Adverse events by body system and specific adverse events

From: Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

  Number of Percent with   
Outcome Trials Patients Ferric
carboxymaltose
Control RB or RR
95% CI
NNTp/H
95% CI
Comparison with oral iron
Body system and preferred term
GI disorder 5 1539 13 32 0.44 (0.36 to 0.54) 5.4 (4.4 to 7.1)
General, administrative site 5 1539 11 4 2.8 (1.9 to 4.2) 15 (11 to 24)
Infection, infestation 5 1539 14 12 1.2 (0.9 to 1.6) not calculated
Metabolism, nutrition, investigation 4 1195 11 5 2.2 (1.4 to 3.4) 17 (11 to 33)
Nervous system 5 1539 10 9 1.3 (0.9 to 1.7) not calculated
Specific adverse events
Constipation 4 1339 3 13 0.3 (0.2 to 0.4) 9.8 (7.6 to 14)
Diarrhoea 3 906 2 5 0.5 (0.2 to 0.9) 33 (18 to 230)
Nausea/vomiting 3 906 3 10 0.4 (0.2 to 0.6) 14 (9.5 to 27)
Headache 5 1539 7 7 1.2 (0.8 to 1.7) not calculated
Comparison with IV saline
Body system and preferred term
GI disorder 2 1577 8 5 1.6 (1.1 to 2.4) 34 (19 to 210)
General, administrative site 2 1577 6 2 2.5 (1.5 to 4.3) 25 (17 to 49)
Infection, infestation 2 1577 9 6 1.1 (0.8 to 1.6) not calculated
Nervous system 2 1577 8 6 1.2 (0.9 to 1.8) not calculated
Respiratory system 2 1577 2 2 0.8 (0.4 to 1.5) not calculated
  1. Note NNTp in normal text, NNH when bold